ATIPAMEZOLE HYDROCHLORIDE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C14H16N2.ClH
Molecular Weight	248.751
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.CCC1(CC2=C(C1)C=CC=C2)C3=CN=CN3

InChI

InChIKey=PCCVCJAQMHDWJY-UHFFFAOYSA-N

InChI=1S/C14H16N2.ClH/c1-2-14(13-9-15-10-16-13)7-11-5-3-4-6-12(11)8-14;/h3-6,9-10H,2,7-8H2,1H3,(H,15,16);1H

HIDE SMILES / InChI

Description
Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=403065e1-4c1a-433c-bb1b-6a2951946297
Curator's Comment: description was created based on several sources, including: http://www.fda.gov/downloads/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/FOIADrugSummaries/ucm116099.pdf https://www.zoetisus.com/products/dogs/antisedan-_atipamezole_.aspx

Atipamezole is a synthetic α2-adrenergic antagonist. It competitively inhibits α2-adrenergic receptors. Atipamezole is indicated for the reversal of the sedative and analgesic effects of Dexdomitor and Domitor in dogs. Adverse reactions: occasional vomiting may occur. At times, a period of excitement or apprehensiveness may be seen in dogs treated with atipamezole. Other effects of atipamezole include hypersalivation, diarrhea, and tremors.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Adrenergic receptor alpha-2 113 Target ID: CHEMBL2095158 Sources: http://www.ncbi.nlm.nih.gov/pubmed/9402036 \| https://www.ncbi.nlm.nih.gov/pubmed/16389294	Antagonist 2778		1.6 nM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Sedative and analgesic effects of Dexdomitor and Domitor 2 Sources: http://www.fda.gov/downloads/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/FOIADrugSummaries/ucm116099.pdf	Primary		Approved 8429	Antisedan Approved Use It is indicated for the reversal of the clinical effects of the sedative and analgesic agents. Launch Date 1996

PubMed

Title	Date	PubMed
Rapid reversal of alpha 2-adrenoceptor agonist effects by atipamezole in human volunteers.	1991 Feb	1675577
Systemic administration of atipamezole, an alpha 2-antagonist, can reduce scopolamine-induced hyperactivity in rats.	1997 Oct	9832985
Altered glucose homeostasis in alpha2A-adrenoceptor knockout mice.	2004 Nov 28	15556159
Anticataleptic properties of alpha2 adrenergic antagonists in the crossed leg position and bar tests: differential mediation by 5-HT1A receptor activation.	2005 Feb	15448976
Benzo(alpha)pyrene-induced up-regulation of CYP1A2 gene expression: role of adrenoceptor-linked signaling pathways.	2006 Jun 20	16510159
Seizures during medetomindine sedation and local anaesthesia in two dogs undergoing skin biopsy.	2009 May	19382926

Patents

Sample Use Guides

In Vivo Use Guide

The atipamezole dose for the reversal of Dexdomitor or Domitor is 3750 ug/m2 (intravenous) or 5000 ug/m2 (intramuscular).

Route of Administration: Other

In Vitro Use Guide

Affinity of atipamezole to a1- and a2-adrenoceptors in rat brain membranes is 13,300 and 1.6 nM respectively.

Name

Type

Language

ATIPAMEZOLE HYDROCHLORIDE

Common Name

English

ATIPAMEZOLE HYDROCHLORIDE [GREEN BOOK]

Common Name

English

ATIPAMEZOLE HYDROCHLORIDE [MI]

Common Name

English

ATIPAMEZOLE HYDROCHLORIDE [MART.]

Common Name

English

ATIPAMEZOLE HCL

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29713